Introduction
============

Retinitis pigmentosa (RP) is a group of hereditary retinal diseases characterized by night blindness and progressive loss of the visual field. It has a prevalence of about 1 in 4000 \[[@r1]\]. RP was the major cause of visual impairment among persons who entered 29 rehabilitation centers in Japan, accounting for 25% of these cases \[[@r2]\]. RP is a disease with considerable genetic heterogeneity; it is transmitted as an autosomal dominant, autosomal recessive, X-linked, or rare mitochondrial form. Moreover, digenic or syndromic forms of RP complicate inheritance patterns \[[@r3],[@r4]\]. The frequency of the inherited type has been estimated as follows: 19% dominant, 65% recessive or isolated, 8% X-linked, and 8% undetermined in Maine in the United States \[[@r5]\]; 16.9% dominant, 25.2% recessive, 1.6% X-linked, and 56.3% simplex in a study of Japanese RP patients \[[@r6]\].

So far, positional cloning and candidate gene screening have identified at least 36 loci responsible for RP \[[@r3]\] (for the latest summary, see the [RetNet](http://www.sph.uth.tmc.edu/Retnet/) page). Of the genes known to cause autosomal dominant RP (adRP) in the United States and Canada, mutations in a rhodopsin (RHO) gene were most frequently observed, accounting for 24-29% of cases \[[@r7]-[@r9]\]. Since *RHO* was identified as an RP-causing gene \[[@r10]\], a number of mutations have been found at a variety of sites on the *RHO* locus \[[@r1],[@r7]-[@r9]\] (for the latest summary, see [RHO](http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RHO)). Most rhodopsin mutations cause adRP, whereas a few have been reported to cause autosomal recessive RP (arRP) \[[@r11],[@r12]\] or congenital stationary night blindness \[[@r13]-[@r15]\]. In a total of 85 Japanese adRP patients, the following five causative mutations in RHO have been reported: Asn15Ser \[[@r16]\], Thr17Met \[[@r17]\], Gly106Arg \[[@r18]\], Glu181Lys \[[@r19]\], Pro347Leu \[[@r17]\]. The rate of RHO mutations in Japanese (5/85, 5.9%) is lower than that in the United States, suggesting a race-dependent mutation rate \[[@r20]\].

A single-stranded conformation polymorphism method targeting the coding regions has been frequently used for the first screening of mutations \[[@r7]-[@r9],[@r11]\], but this method intrinsically includes the possibility of missing mutations. Mutations in a promoter region or introns may also be responsible for arRP by affecting the levels of expression of *RHO* \[[@r13]\]. These problems with mutation screening can be resolved by sequencing the entire region of the *RHO* locus. Furthermore, full sequencing provides information about single nucleotide polymorphism (SNPs) and haplotypes that could affect the expression levels of the gene. Promoter haplotype combinations have been shown to affect the biological and therapeutic phenotypes by altering the expression of the gene for β2-adrenergic receptor \[[@r21]\]. This led us to hypothesize that *RHO* promoter haplotypes are associated with susceptibility to RP via a mechanism that changes the levels of expression of *RHO*. A search for RP-related SNPs in *RHO* was carried out \[[@r22]\], but there has been no report on the haplotype structure of *RHO* to date.

In the present study, we determined the full sequence of the *RHO* locus, including the promoter regions and introns, in order to search for RP-associated mutations and/or haplotypes in the *RHO* loci of RP patients who visited the low-vision clinic at our center.

Methods
=======

Subjects
--------

We studied 68 unrelated RP patients who visited the low-vision clinic at our center. RP subjects were selected on the basis of clinical findings, patient history, and family history. Of these 68 patients, 26 had a family history, 27 had no family history, and 15 had an unknown family history. [Table 1](#t1){ref-type="table"} shows the detailed information on the 26 subjects with a family history. Five of these patients had an affected parent with RP or night blindness, and the patient designated as RP048 reported having an affected sibling whose son suffers from RP. Thus, these six cases were diagnosed as adRP. Seven patients with grandparents or cousins with RP or night blindness could have suffered from adRP. RP051 and RP062 reported a family history of consanguineous marriage. Control samples were obtained from students at the college affiliated with our center and from members of our staff of the center, all of whom declared having neither a personal history nor a family history of night blindness or unexplained visual loss. The study was approved by the Human Genome-Ethics Committee of the National Rehabilitation Center for Persons with Disabilities and was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects involved in this study.

###### Information on retinitis pigmentosa patients with a family history.

  ------------ ---------------- --------- ------------------------ --------------------------------- ------------------------------ -------------------------
  **Number**   **Patient ID**   **Sex**   **Number of siblings**   **Number of affected siblings**   **Other affected relatives**   **Type of inheritance**
  1            RP005            F         6                        2                                 Mother (RP)                    ad
  2            RP008            F         7                        2                                                                
  3            RP009            F         4                        2                                 Grandmother (NB)               ad(?)
  4            RP010            F         4                        3                                                                
  5            RP016            F         8                        3                                 Grandmother (RP?)              ad(?)
  6            RP017            F         5                        2                                                                
  7            RP020            F         3                        1                                 Cousin (central vision loss)   ad(?)
  8            RP021            M         3                        2                                                                
  9            RP022            M         3                        1                                 Grandfather (RP?)              ad(?)
  10           RP023            M         7                        2                                                                
  11           RP024            M         2                        2                                 Grandmother (RP?)              ad(?)
  12           RP029            M         3                        2                                 Mother (NB), cousin (RP)       ad
  13           RP034            F         5                        1                                 Father (NB), cousin (RP?)      ad
  14           RP035            M         3                        1                                 Father (RP)                    ad
  15           RP036            F         8                        5                                 Distant relative (RP?)         ad(?)
  16           RP037            F         3                        1                                 Mother(RP)                     ad
  17           RP038            F         4                        1                                 Cousin(RP)                     ad(?)
  18           RP039            M         2                        2                                                                
  19           RP044            F         6                        2                                                                
  20           RP045            M         10                       4                                                                
  21           RP048            M         4                        3                                 Affected sib\'s son (RP)       ad
  22           RP051            F         2                        2                                 Consanguineous marriage        ar
  23           RP061            M         4                        2                                                                
  24           RP062            M         4                        2                                 Consanguineous marriage        ar
  25           RP063            M         6                        3                                                                
  26           RP064            F         7                        3                                                                
  ------------ ---------------- --------- ------------------------ --------------------------------- ------------------------------ -------------------------

Of 68 unrelated RP patients who visited the low-vision clinic at our center, 26 had a family history. Sex: Male (M), Female (F). Siblings and affected siblings include the proband. NB indicates night blindness. Inheritance type: ad indicates autosomal dominant; ar indicates autosomal recessive.

DNA sample preparation
----------------------

Genomic DNA was isolated from venous blood using a PUREGENE DNA purification Kit (Gentra Systems, Minneapolis, MN). A sample for DNA sequencing was prepared by polymerase chain reaction (PCR) using genomic DNA as a template. The genomic sequence of the *RHO* locus (NT_005612.15) was retrieved from NCBI database (Build 36.1). Nucleotide A of the initiation codon of *RHO* was defined as Position 1. The primer sequences for PCR amplification are listed in [Table 2](#t2){ref-type="table"}. The first PCR amplification was performed in order to obtain two amplicons, A1 (containing *RHO* exons and introns) and A2 (containing the promoter region of *RHO*). Two hundred nanograms of genomic DNA were amplified with Taq polymerase (TaKaRa Ex Taq® Takara Bio Inc., Shiga, Japan) in a 50 μl reaction volume for 30 cycles under conditions of heating for 30 s at 96 °C, annealing for 30 s at 63 °C, and extension for 2 min at 72 °C. The second PCR amplification using amplicon A1 as a template produced 4 amplicons (A3, A4, A5, A6).

###### Polymerase chain reaction primers used for amplifying the *rhodopsin* gene locus.

  -------------- ------------ -------------- ------------------------------------------
  **Amplicon**   **Primer**   **Position**   **Sequence (5\'-\>3\')**
  A1             A1F          -297           aaggccgcctcggCCTGGATCCTGAGTACCTCTCCTC
                 A1R          6605           aagcggccgcTTTTCCCATTCCCAGGACTGCCTCCTCCAC
  A2             A2F          -1260          CAGTCATCTGCCCCCAAGGC
                 A2R          142            TCAGCAGAAACATGTAGGCG
  A3             A1F          -297           aaggccgcctcggCCTGGATCCTGAGTACCTCTCCTC
                 A3R          2402           CCTGGAACCAGACACTACTG
  A4             A4F          1951           GCTCTCCTCAGCGTGTGGTC
                 A4R          4669           GCTGTGTCACCCGTGACATTTCAT
  A5             A5F          3735           CATGCATCTGCGGCTCCTGCTC
                 A5R          6010           CTTCCAGAGGCTGAGAGAAAGGCC
  A6             A6F          5085           GAACGAAGTCACATAGGCTCC
                 A1R          6605           aagcggccgcTTTTCCCATTCCCAGGACTGCCTCCTCCAC
  -------------- ------------ -------------- ------------------------------------------

Position 1 corresponds to the nucleotide A of the initiation codon of the RHO gene. Lower letters represent an artificial sequence added for cloning the polymerase chain reaction products.

Sequencing
----------

PCR products were sequenced bi-directionally with a BigDye® Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) using the primers listed in [Table 3](#t3){ref-type="table"}. Sequencing reaction products were run on an automated capillary sequencer (Applied Biosystems 3130xl Genetic Analyzer, Applied Biosystems, Foster City, CA).

###### Primers used for sequencing.

  ------------- -------------- --------------------------
  **Primer**    **Position**   **Sequence (5\'-3\')**
  **Forward**                  
  SF01          -926           CTAGCGTTCAAGACCCATTAC
  SF02          -452           GAGAGACTGGGAGAATAAACC
  SF03          153            CTTCCCCATCAACTTCCTCACG
  SF04          592            TGCGCTTGTCTAATTTCACAGC
  SF05          1053           GGAAAACAGATGGGGTGCTGC
  SF06          1476           CTTTCACTGTTAGGAATGTCC
  SF07          1951           GCTCTCCTCAGCGTGTGGTC
  SF08          2383           CAGTAGTGTCTGGTTCCAGG
  SF09          2860           CCTCCTCAGTCTTGCTAGGGTC
  SF10          3289           GGTGTCATCTGGTAACGCAG
  SF11          3735           CATGCATCTGCGGCTCCTGCTC
  SF12          4144           TGGCAGCAGTCTTGGGTCAGC
  SF13          4616           ACAGAACACCCTTGGCACACAGAG
  SF14          5085           GAACGAAGTCACATAGGCTCC
  SF15          5360           GATGGATGCAGGAAGGAATGGAGG
  SF16          5548           CTGAGAAGACCAAAAGAGGTG
  SF17          5987           GGCCTTTCTCTCAGCCTCTGGAAG
  SF18          6444           GGGTTTTGTTGCTTTCACACTC
  **Reverse**                  
  SR01          -775           GTGGCTGTGAGGTTGTGGAGAC
  SR02          -284           ACTCAGGATCCAGGAAAAGG
  SR03          174            CGTGAGGAAGTTGATGGGGAAG
  SR04          613            GCTGTGAAATTAGACAAGCGCA
  SR05          1073           GCAGCACCCCATCTGTTTTCC
  SR06          1496           GGACATTCCTAACAGTGAAAG
  SR07          1970           GACCACACGCTGAGGAGAGC
  SR08          2402           CCTGGAACCAGACACTACTG
  SR09          2881           GACCCTAGCAAGACTGAGGAGG
  SR10          3308           CTGCGTTACCAGATGACACC
  SR11          3756           GAGCAGGAGCCGCAGATGCATG
  SR12          4204           GCCAGGAATCTGCATTTCTCAC
  SR13          4669           GCTGTGTCACCCGTGACATTTCAT
  SR14          5105           GGAGCCTATGTGACTTCGTTC
  SR15          5568           CACCTCTTTTGGTCTTCTCAG
  SR16          6010           CTTCCAGAGGCTGAGAGAAAGGCC
  SR17          6465           GAGTGTGAAAGCAACAAAACCC
  ------------- -------------- --------------------------

Position 1 corresponds to the nucleotide A of the initiation codon of the *RHO* gene.

Haplotype analysis
------------------

Haplotypes were estimated from unphased genotypes using Clark\'s algorithm \[[@r23]\] and the expectation-maximization (EM) algorithm \[[@r24]\]. Phylogenetic analysis was carried out with the minimum spanning network (MSN) algorithm \[[@r25]\]. The Arlequin program (Schneider, Roessli, Excoffier, [Arlequin](http://lgb.unige.ch/arlequin/) version 2.000: A software for population genetics data analysis, Geneva, Switzerland) was used for the analysis using the EM algorithm and the MSN algorithm.

Results
=======

Sequence variations
-------------------

[Table 4](#t4){ref-type="table"} shows the sequence variations obtained in this study. We identified a total of 41 sequence variations consisting of 39 single nucleotide substitutions, one insertion/deletion polymorphism (Indel, SV15), and one CA-repeat polymorphism (SV16) in a total of 272 chromosomes from 68 RP patients and 68 controls. Of 39 single nucleotide substitutions, 25 sites were novel ones not registered in the dbSNP database (National Center of Biotechnology Information). This study did not find four substitutions (rs2855553, rs2855556, rs2625964, rs2625969) registered in the dbSNP, which seem to be rare among Japanese. Rare substitutions with less than 1% minor allele frequency (MAF) occurred at 17 sites, nine of which were observed only in the RP patients and six only in the controls.

###### Nucleotide sequence variations observed in the *rhodopsin* gene locus.

  ----------------- -------------- ------------ -------------- -------------- ------------------------- -------------- -------------------------------- --------- --------- ---------- ---------------
                                                                                                                       **Minor allele frequence (%)**                                  
  **Marker name**   **SNP name**   **Region**   **Amplicon**   **Position**   **Alleles major/minor**   **dbSNP ID**   **RP**                           **Ctl**   **Sum**   **JSNP**   **JSNP ID**
  SV01              SNP01          Upstream     A2             -1163          C/T                       rs2625954      42.6                             41.9      42.3      \-         \-
  SV02              SNP02          Upstream     A2             -778           A/C                       rs2625955      41.9                             41.9      41.9      42         IMS-JST108944
  SV03              \-             Upstream     A2             -598           G/A                       \-             0.7                              0         0.4       \-         \-
  SV04              SNP03          Exon 1       A2, A3         -51            G/A                       rs2269736      33.8                             28.7      31.3      33.2       IMS-JST024023
  SV05              SNP04          Exon 1       A2, A3         -26            G/A                       rs7984         43.4                             41.2      42.3      41.2       IMS-JST024024
  SV06              \-             Exon 1       A2, A3         124            G/A(Ala42Thr)             \-             0                                0.7       0.4       \-         \-
  SV07              \-             Exon 1       A3             273            C/T(Phe91Phe)             \-             0.7                              0         0.4       \-         \-
  SV08              \-             Exon 1       A3             315            C/T(Phe105Phe)            \-             0.7                              0         0.4       \-         \-
  SV09              SNP05          Intron 1     A3             668            A/G                       \-             5.9                              3.7       4.8       \-         \-
  SV10              SNP06          Intron 1     A3             709            C/T                       \-             5.9                              5.1       5.5       \-         \-
  SV11              \-             Intron 1     A3             794            G/A                       \-             0                                0.7       0.4       \-         \-
  SV12              \-             Intron 1     A3             966            C/T                       \-             0.7                              0         0.4       \-         \-
  SV13              SNP07          Intron 1     A3             1349           T/G                       rs2855552      29.4                             30.1      29.8      28.3       IMS-JST130259
  SV14              \-             Intron 1     A3             1354           C/T                       \-             1.5                              1.5       1.5       \-         \-
  \-                \-             Intron 1     \-             1535           G/A                       rs2855553      \-                               \-        \-        \-         \-
  SV15              \-             Intron 1     A3             1751-1760      AGGATGCATT/del            \-             22.1                             19.1      20.6      \-         \-
  SV16              \-             Intron 1     A3             1775-1835      (CA)nA(CA)m               \-             \-                               \-        \-        \-         \-
  SV17              SNP08          Intron 2     A4             2703           G/T                       rs6803468      0.7                              3.7       2.2       \-         \-
  SV18              SNP09          Intron 2     A4             2718           C/T                       \-             5.9                              5.1       5.5       \-         \-
  SV19              SNP10          Intron 2     A4             2750           G/A                       rs6803484      0.7                              3.7       2.2       \-         \-
  \-                \-             Intron 2     \-             2760           A/T                       rs2855556      \-                               \-        \-        \-         \-
  SV20              \-             Intron 2     A4             2753           A/G                       \-             0                                0.7       0.4       \-         \-
  SV21              \-             Intron 2     A4             2787           G/A                       \-             1.5                              0         0.8       \-         \-
  SV22              SNP11          Intron 2     A4             2990           G/A                       \-             22.1                             19.9      21        \-         \-
  SV23              SNP12          Intron 2     A4             3217           C/T                       \-             5.9                              5.1       5.5       \-         \-
  SV24              \-             Intron 2     A4             3269           C/T                       \-             0.7                              0         0.4       \-         \-
  SV25              \-             Intron 2     A4             3397           G/A                       \-             0.7                              0.7       0.7       \-         \-
  SV26              SNP13          Intron 3     A4             3687           C/T                       \-             5.9                              5.1       5.5       \-         \-
  SV27              \-             Exon 4       A4, A5         3994           C/T(Ser297Ser)            \-             1.5                              1.5       1.5       \-         \-
  SV28              \-             Intron 4     A4, A5         4056           G/T                       \-             1.5                              0         0.8       \-         \-
  SV29              SNP14          Intron 4     A4, A5         4346           T/A                       rs2855557      41.9                             42.6      42.3      \-         \-
  \-                \-             Intron 4     \-             4730           T/A                       rs2625964      \-                               \-        \-        \-         \-
  SV30              SNP15          Intron 4     A5             4852           G/A                       rs2071092      29.4                             30.1      29.8      28.8       IMS-JST006396
  SV31              SNP16          Exon 5       A5             5028           C/A                       rs2071093      5.9                              5.1       5.5       4.3        IMS-JST006397
  SV32              \-             Exon 5       A5, A6         5216           C/T                       \-             0.7                              0         0.4       \-         \-
  SV33              SNP17          Exon 5       A5, A6         5217           G/A                       rs2410         48.5                             49.3      48.9      \-         \-
  SV34              \-             Exon 5       A5, A6         5426           G/A                       \-             0.7                              0.7       0.7       \-         \-
  \-                \-             Exon 5       \-             5833           A/G                       rs2625969      \-                               \-        \-        \-         \-
  SV35              SNP18          Exon 5       A5, A6         5897           G/A                       rs2855558      41.9                             41.9      41.9      42.5       IMS-JST086767
  SV36              SNP19          Exon 5       A5, A6         5910           T/C                       \-             0.7                              2.9       1.8       \-         \-
  SV37              \-             Exon 5       A5, A6         5914           C/T                       \-             0                                0.7       0.4       \-         \-
  SV38              \-             Exon 5       A6             5944           A/G                       \-             0.7                              0         0.4       \-         \-
  SV39              SNP20          Exon 5       A6             6084           G/A                       rs3733148      8.8                              19.9      14.4      15.1       IMS-JST086768
  SV40              \-             Exon 5       A6             6129           C/T                       \-             0                                0.7       0.4       \-         \-
  SV41              \-             Exon 5       A6             6193           G/A                       rs3733149      0                                0.7       0.4       0.8        IMS-JST086769
  ----------------- -------------- ------------ -------------- -------------- ------------------------- -------------- -------------------------------- --------- --------- ---------- ---------------

The amino acid substitution caused by nucleotide substitution was represented in parenthesis. Individual SNPs were characterized in 68 patients (RP) and 68 controls (Ctl). A database of Japanese single nucleotide polymorphisms (JSNP) contains nine SNPs that were measured in 732-746 Japanese subjects.

Twenty substitutions with a MAF of greater than 1% showed linkage disequilibrium (LD) between pairs, and these substitutions were designated as SNP01 to SNP20. These SNPs were consistent with the Hardy-Weinberg equilibrium (data not shown). SV14 and SV27 exhibited 1.5% of the MAF, but were excluded from the SNPs due to the absence of LD pairs. Most SNPs with a MAF of greater than 10% were registered in the dbSNP, with the exception of SNP11. Nine SNPs were registered in a database of Japanese single nucleotide polymorphisms ([JSNP](http://snp.ims.u-tokyo.ac.jp/)) and the MAF values of these substitutions were similar to each other at each site, except in the case of SNP20. The differences between RP patient and control MAFs were small, except in the case of SNP20. The MAF at SNP20 was 8.8% among RP patients and 19.9% among controls, respectively. However, the mean MAF of all subjects at SNP20 was 14.4%, which is similar to the value described in the JSNP database, i.e., 15.1% (1488 chromosomes).

Four rare single nucleotide substitutions were observed in the coding region. Three substitutions (SV07, SV08, and SV27) were synonymous. On the other hand, SV06 observed in 1 control led to an amino acid substitution (Ala42Thr). SV03 was observed in the promoter region of one RP patient, and it was located at position -503 upstream of the transcription start site \[[@r26]\].

Intron 1 was found to contain an Indel of 10bp (SV15) followed by a CA-repeat polymorphism (SV16, (CA)nA(CA)m, n=12-14, m=15-27). The precise number of repeats was not determined due to degeneration of sequences.

Haplotypes
----------

Haplotypes of the *RHO* locus were estimated on the basis of 20 SNPs of 272 chromosomes obtained from patients and controls. Indel variation SV15 was also taken into account, because it was found to be linked to SNP11. [Table 5](#t5){ref-type="table"} shows 14 haplotypes consisting of eight major haplotypes and six rare ones. The rare haplotypes (H09-H14) appeared to be the result of a single conversion in the corresponding major haplotype. There were five groups of LD structures of SNPs and an Indel: SNP01-SNP02-SNP04-SNP14-SNP18, SNP06-SNP09-SNP12-SNP13-SNP16, SNP07-SNP15, SNP08-SNP10-SNP19, and SNP11-SV15. Eight major haplotypes can produce 36 combinations, in which 29 were identified in 136 subjects. Seven major haplotypes, except for H08, were found to exist as a homozygote. The most frequent haplotype, H01, accounted for 27.2% of a total of 272 chromosomes. The present comparison of haplotype frequencies did not reveal any significant differences between RP patients and controls when taking into account the multiple comparisons. With a Bonferroni correction for the eight comparisons, a p-value of 0.05/8=0.006 is required for statistical significance.

###### Haplotypes of the Japanese *rhodopsin* gene locus.

  -------------------- -------------- --------------------------- ---------- ------------- --- --- --- ------- --- --- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ------- ----- ----- ----- ----------- ------ -------
  **Haplotype name**   **SNP name**   **Number of chromosomes**   **χ^2^**   **p value**                                                                                                                              
                       1              2                           3          4             5   6   7   Indel   8   9   10   11   12   13   14   15   16   17   18   19   20      RP    Ctl   Sum   Frequency          
  H01                  T              C                           G          A             A   C   T   Ins     G   C   G    G    C    C    A    G    C    A    A    T    G       45    29    74    0.272       4.75   0.029
  H02                  C              A                           A          G             A   C   T   Del     G   C   G    A    C    C    T    G    C    G    G    T    G       30    26    56    0.206       0.36   0.548
  H03                  T              C                           G          A             A   C   T   Ins     G   C   G    G    C    C    A    G    C    A    A    T    A       12    27    39    0.143       6.73   0.009
  H04                  C              A                           G          G             A   C   G   Ins     G   C   G    G    C    C    T    A    C    G    G    T    G       16    23    39    0.143       1.47   0.225
  H05                  C              A                           A          G             A   C   G   Ins     G   C   G    G    C    C    T    A    C    G    G    T    G       15    13    28    0.103       0.16   0.69
  H06                  C              A                           G          G             A   T   T   Ins     G   T   G    G    T    T    T    G    A    A    G    T    G       8     6     14    0.051       0.3    0.583
  H07                  C              A                           G          G             G   C   G   Ins     G   C   G    G    C    C    T    A    C    G    G    T    G       8     4     12    0.044       1.39   0.238
  H08                  C              A                           G          G             A   C   T   Ins     T   C   A    G    C    C    T    G    C    A    G    C    G       1     3     4     0.015       1.01   0.313
  H09                  T              C                           G          G             A   C   T   Ins     G   C   G    G    C    C    A    G    C    A    A    T    G       0     1     1     0.004              
  H10                  T              A                           A          G             A   C   G   Ins     G   C   G    G    C    C    T    A    C    G    G    T    G       1     0     1     0.004              
  H11                  C              A                           G          G             A   T   G   Ins     G   T   G    G    T    T    T    G    A    A    G    T    G       0     1     1     0.004              
  H12                  C              A                           G          G             G   C   T   Ins     G   C   G    G    C    C    T    A    C    G    G    T    G       0     1     1     0.004              
  H13                  C              A                           G          G             A   C   T   Ins     T   C   A    G    C    C    A    G    C    A    G    C    G       0     1     1     0.004              
  H14                  C              A                           G          G             A   C   T   Ins     T   C   A    G    C    C    T    G    C    A    G    T    G       0     1     1     0.004              
                                                                                                                                                                         Total   136   136   272   1.000              
  -------------------- -------------- --------------------------- ---------- ------------- --- --- --- ------- --- --- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ------- ----- ----- ----- ----------- ------ -------

A total of 136 subjects comprised of 68 retinitis pigmentosa patients (RP) and 68 controls (Ctr) were analyzed. One insertion/deletion (Indel) variation was linked to SNP11. Red letters represent haplotype-tagging SNPs.

Phylogeny of *rhodopsin* gene haplotypes
----------------------------------------

The phylogeny of *RHO* haplotypes was calculated using the minimum spanning network algorithm ([Figure 1](#f1){ref-type="fig"}). The area of the circle is proportional to the frequency of each haplotype. The ratio of RP patients (orange) and controls (light blue) for each haplotype is color-coded. The number of line segments between circles corresponds to the number of nucleotide substitutions between haplotypes. The graph in [Figure 1](#f1){ref-type="fig"} shows that the *RHO* haplotypes can be classified into five groups separated by a large number of nucleotide substitutions. The groups are designated as Group I to Group V. The haplotype-tagging SNP (htSNP) distinguishing each group is described in the parenthesis following the group name in the [Figure 1](#f1){ref-type="fig"}. Furthermore, the htSNP distinguishing each haplotype in the group is described in parenthesis following the haplotype name. These htSNPs can be used as markers to estimate the haplotype of new subjects.

![Phylogeny of Japanese *rhodopsin* gene haplotypes. The area of the circle is proportional to the frequency of each haplotype. The ratio of RP patients (orange) and controls (light blue) for each haplotype is color-coded. The number of line segments between circles corresponds to the number of nucleotide substitutions between haplotypes. The *RHO* haplotypes can be classified into five groups designated as Group I to Group V. The haplotype-tagging SNP (htSNP) distinguishing each group is described in the parentheses following the group name and the haplotype name.](mv-v13-1038-f1){#f1}

Discussion
==========

In this study, we did not detect any causative mutation in the coding region of the RHO gene of 68 Japanese RP patients. Five mutations in RHO have been reported to date for a total of 85 Japanese adRP patients \[[@r16]-[@r19]\]; thus, the prevalence of causative mutations in RHO is calculated to be 5.9%, suggesting that RHO mutations may be among the common causes of adRP in Japan. Based on the estimated number (at most 13) of adRP patients in this study, the predicted number of cases with a RHO mutation was less than 1. Thus, the present results are consistent with those of previous studies, indicating that the rate of RHO mutations in Japanese adRP is low compared to that of the American population. It should be noted that more frequent occurrence of RHO mutations in the American patients is partially due to the presence of a large number of families carrying Pro23His \[[@r27]\], which likely originated from a single ancestor \[[@r28]\].

Unexpectedly, one novel heterozygous variation causative of an amino acid substitution (Ala42Thr) was found in 1 control subject. This variation exists in the first transmembrane domain. To date, eleven pathogenic variations have been reported in the first transmembrane domain of [RHO](http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RHO). The Ala residue at position 42 is fairly conserved among vertebrate opsins. Of 143 reported vertebrate opsin sequences, 130 have an Ala at position 42, whereas 12 have Cys and 1 has Ser at that position (GPCRDB: Information system for G protein-coupled receptors ([gpcr](http://www.gpcr.org/7tm/)), release 10.0) \[[@r29]\]. The amino acid change from a nonpolar Ala to a polar and slightly larger Thr could affect the conformation of the first transmembrane domain. A similar substitution close to the 42nd Ala, Met44Thr, has been reported in a patient with a simplex case of RP \[[@r30]\]. These findings suggest that Ala42Thr could be a pathogenic mutation. However, the control subjects reported having no symptoms such as night blindness or other visual impairments, nor was there any family history of visual impairments. There are three possibilities that might account for the discrepancy between the predicted pathogenic phenotype and the apparently silent phenotype of the carrier. The first possibility would be that Ala42Thr is a rare benign variation. In fact, four nonpathogenic missense changes have been reported thus far: Thr70Met \[[@r9]\], Val104Ile \[[@r31]\], Pro220Leu \[[@r27]\], and Gly284Ser \[[@r32]\]. On the other hand, a missense change, Glu150Lys, caused recessive RP \[[@r12]\], and this second possibility suggests that the Ala42Thr change might be a recessive mutation. The third possibility would be that the symptoms were sufficiently mild to escape the notice of the carrier. Unfortunately, this issue remains unsolved, as we were unable to obtain any clinical information on this subject.

Full sequencing of the *RHO* locus has revealed the presence of variations in the promoter region and introns. Seven heterozygous variations occurred only in the RP patients: 1 in the promoter region, 4 in the introns, and 2 in the 3\'-UTR. Although we cannot deny the possibility of causative mutations, most cases may be rare variations. SV03 is located at position -503 upstream of the transcription start site. This region did not show significant homology with the bovine *RHO* promoter \[[@r33]\], and the corresponding bovine sequence was not included in the protected regulatory elements determined by DNase I footprint experiments \[[@r34]\]. We were also unable to identify regulatory elements for retina-specific transcription factors such as CRX, NRL, and NR2E3 \[[@r35]\] in this region. These results suggest that SV03 is unlikely to affect promoter activity. This issue should be resolved in future experiments by measuring the promoter activity of SV03 variants.

The fine mapping of SNPs has revealed eight haplotype structures of the *RHO* locus in the Japanese population. The haplotypes obtained are classified into five groups that may stem from distinct Japanese ancestors. If a causative mutation is associated with a specific haplotype, it may stem from a single ancestor. From this perspective, it would be of interest to determine which haplotypes carry frequent mutations such as Pro23His and Pro347Leu \[[@r8]\].

Unfortunately, we were unable to identify RP-associated SNPs or haplotypes. Our first expectation was that the haplotype of the promoter region may be associated with RP by altering the levels of expression of *RHO*. The promoter region contains five SNPs (SNP01-SNP05) that construct four haplotypes. Assessment of frequencies of these four haplotypes did not reveal any significant differences between RP patients and controls (data not shown), suggesting that there is no association between susceptibility to RP and the *RHO* promoter haplotype.

In conclusion, this was the first study to determine the comprehensive sequence variations and haplotype structure of the *RHO* locus, including the promoter region and introns. No causative mutation in *RHO* was observed in 68 Japanese patients with RP, but 1 control subject had a novel amino acid substitution, Ala42Thr, which may have been benign. Although we were unable to identify any RP-associated SNPs or haplotypes, the htSNPs identified here will be useful as markers for the linkage-based screening of RP patients.
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